Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CTNNB1 |
Variant | A97fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | CTNNB1 A97fs results in a change in the amino acid sequence of the Ctnnb1 protein beginning at aa 97 of 781, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), A97fs is predicted to lead to a loss of Ctnnb1 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
CTNNB1 mutant CTNNB1 inact mut CTNNB1 A97fs |
Transcript | NM_001098210.2 |
gDNA | chr3:g.(41225000_41225001) |
cDNA | c.(289_288) |
Protein | p.A97fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_024453356.2 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_024453356.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_047447477.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_005264886 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
NM_001098210.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_024453357.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
NM_001904 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_047447483.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_006712985 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
NM_001098209.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
NM_001904.4 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_024453358.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
NM_001098209.2 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_006712985.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
NM_001098210.2 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_047447478.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
NM_001098209 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_017005738.2 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_047447479.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
NM_001098210 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_017005738.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_047447481.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_006712985.2 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_047447480.1 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
NM_001904.3 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
XM_017005738 | chr3:g.(41225000_41225001) | c.(289_288) | p.A97fs | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|